Company coronavirus news summary – Moderna expands vaccine manufacturing capacity – Takeda starts dosing participants in Japanese trial of Novavax’s Covid-19 vaccine

25 February 2021 (Last Updated February 25th, 2021 08:56)

25 February 2021

Takeda announced that the first participant has been dosed with Novavax’s Covid-19 vaccine candidate (TAK-019) in Japan in a Phase I/II immunogenicity and safety study. Earlier this month, Takeda completed the enrolment of Moderna’s Covid-19 vaccine candidate (TAK-919) in a Phase I/II immunogenicity and safety study in the country. Takeda will manufacture Novavax’s recombinant vaccine and distribute Moderna’s mRNA vaccine with the support of the Japanese government.

The Egyptian Drug Authority has approved the Russian Direct Investment Fund‘s f its Sputnik V vaccine. Egypt is the 35th country in the world to have approved the Covid-19 Sputnik V vaccine for emergency use.

CVS Health added Alabama, Arizona, Louisiana, Florida, Ohio, and Pennsylvania to its list of states where some CVS pharmacy locations will offer Covid-19 vaccinations to eligible populations through the Federal Retail Pharmacy Programme. This follows on from the successful rollout in 11 US states on 12 February 2021.

Moderna is making new investments to boost capacity at its own and partner’s manufacturing facilities in order to increase its global 2022 capacity to about 1.4 billion Covid-19 vaccine doses. The investments will support the increase in production of the Moderna COVID-19 vaccine and potential vaccine boosters needed to address emerging SARS-CoV-2 variants.